ClinicalTrials.gg
Enrolling by invitationNCT02653001Updated Apr 27, 2026

The QIB Colon Model

An interventional study of Stool sample collection in Human Gut Microbiota, sponsored by Quadram Institute Bioscience. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Quadram Institute Bioscience · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this project is to establish a list of volunteers willing and able to donate stool samples for use in the model colon so as to facilitate research directed toward understanding the basic science underlying the interactions between the gut microbiome, potential external modifiers, and health.

Read the detailed description

Adult volunteers will be recruited to donate stool samples for laboratory-based experiments. Once the sample has arrived at QIB 50-100g will be added to the colon model and, depending on the system used, either cultured for 24h or for up to 40 days. During this time, factors under investigation will be added to the model.

Samples added mimic food chyme arriving at the ileal-caecal valve in the intestinal tract. At this stage digested, but non-absorbed food components plus cells and mucous shed from the lining of the small intestine enter the large intestine. Samples of bacteria and media can be taken at any point during the incubation.

Four models are used:

  1. a simple batch culture in which bacteria, media and test compounds are added to a single compartment and analysed over 24h
  2. a three compartment model with continuous flow of media, test compounds and bacteria from the entrance port of the first chamber to the exit of the third chamber mimicking movement through the three main compartments of the colon. This model allows for a stable bacterial population to be established before addition of test compounds, and can remain viable for up to 40 days. In the case of these longer incubations, multiple time points can allow for quite complex experiments looking at interactions between bacteria, food and pharmaceutical products where different factors are added at different time points.

3. a 24-well cassette-based fermenter system (Micro-Matrix Bioreactor) 4. a dynamic model SHIME (Simulator of the Human Intestinal Microbial Ecosystem) (Figure 4).

The SHIME model which is currently the most representative in vitro combined simulation of the gastrointestinal tract in including the three parts of the colon. It's used to study the gut microbiota, and how it interacts with food, drugs, and pathogens.

Samples collected during the incubation will be analysed by centrifuging the sample to create a pellet containing bacteria and a supernatant containing a wide range of metabolites. The bacteria will be analysed by extracting their DNA for genomic analysis or using RNA based approaches. On occasion, conventional microbiological techniques might be used. The supernatant will be filter sterilised prior to analysis of its chemical composition by techniques such as mass spectrometry, gel electrophoresis, or chromatography. Alternatively the supernatant may be added to cell lines to model the interaction between the bacterial ecosystem and the cells lining the colon.

02

Conditions studied

  • Human Gut Microbiota

Keywords

  • in vitro gut model, colon model, stool sample, faecal sample, gut microbiome
03

In context

Lead sponsor

Quadram Institute Bioscience is the lead sponsor of 44 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Live or work within 10 miles of the Norwich Research Park.
  • Having a normal bowel habit; assessed as regular defecation between 3 times a day and 3 times a week, with a form similar to 3-5 on the Bristol Stool Chart.
  • Do not have any diagnosed chronic gastrointestinal health problem, such as irritable bowel syndrome, inflammatory bowel disease, or coeliac disease.

Exclusion criteria

Exclusion Criteria:

This will depend on individual experiments but in most cases samples will not be collected from individuals:

  • who have used antibiotics or probiotics in the last 2 months.
  • who are pregnant or breast feeding.
  • who have recently used other medications or food supplements (considered on a study-specific basis).
  • who have recently had an operation requiring general anaesthetic.
  • who have had a gastrointestinal upset, such as vomiting or diarrhoea within the last 72hrs.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components

    Other: Stool sample collection

Interventions

  • OtherStool sample collection

    Collection of complete stool sample

06

What researchers measure

Primary outcomes

  1. Measurement of 16S rDNA gene (%)

    Measurement of 16S rDNA gene in human stool samples will reflect the bacterial population of the colon.

    Time frame: Across an initial period of ten years

Secondary outcomes

  1. Methane concentration (mmol/L)

    Measurement of methane concentration in gaseous production of human stool samples in colon model.

    Time frame: Across an initial period of ten years

  2. Concentration of short chain fatty acids (mM)

    Concentration of short chain fatty acids in the colon model milieu.

    Time frame: Across an initial period of ten years

  3. Glucosinolate concentration (mM)

    Concentration of glucosinolates in the colon model milieu.

    Time frame: Across an initial period of ten years

  4. Fiber concentration (mM)

    Concentration of fiber in the colon model milieu.

    Time frame: Across an initial period of ten years

07

Study locations

1 site
08

References and documents

Publications

  • Haarhuis JE, Day-Walsh P, Shehata E, Savva GM, Peck B, Philo M, Kroon PA. A Pomegranate Polyphenol Extract Suppresses the Microbial Production of Proatherogenic Trimethylamine (TMA) in an In Vitro Human Colon Model. Mol Nutr Food Res. 2025 Oct;69(20):e70166. doi: 10.1002/mnfr.70166. Epub 2025 Jun 29. PubMed 40583322 ↗
  • Day-Walsh P, Shehata E, Saha S, Savva GM, Nemeckova B, Speranza J, Kellingray L, Narbad A, Kroon PA. The use of an in-vitro batch fermentation (human colon) model for investigating mechanisms of TMA production from choline, L-carnitine and related precursors by the human gut microbiota. Eur J Nutr. 2021 Oct;60(7):3987-3999. doi: 10.1007/s00394-021-02572-6. Epub 2021 May 2. PubMed 33934200 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2015 (actual). Primary completion is estimated for May 2030, 173 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 12, 2016
StartActual
Dec 18, 2015
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02653001
Lead sponsor
Quadram Institute Bioscience
Responsible party
Sponsor
First posted
Jan 12, 2016
Start date
Dec 18, 2015
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Apr 27, 2026

Study contacts

Emad Shehata, Ph.D
principal investigator · Quadram Institute Bioscience

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion